Catheter Precision, Inc. (VTAK) — SEC Financial Statements & Analysis

Catheter Precision, Inc. (VTAK) is a surgical & medical instruments & apparatus company, incorporated in DE. Catheter Precision, Inc. trades on NYSE as: VTAK. Catheter Precision, Inc. (VTAK)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Catheter Precision, Inc. carries a market cap of $2.35M, a P/E ratio of -0.19x, a P/B ratio of 0.14x, a P/S ratio of 1.23x, an enterprise value of $1.71M, and an EV/EBITDA multiple of -0.10x. On profitability, it posts a gross margin of 47.73%, an operating margin of -1000.26%, a net margin of -640.47%, a Return on Equity (ROE) of -103.56%, a Return on Assets (ROA) of -39.29%, and a Return on Invested Capital (ROIC) of -134.78%. Per share, it reports EPS of $-4.43, diluted EPS of $-6.09, free cash flow per share of $-3.39, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 219.17% year-over-year, net income growth of -49.02% year-over-year, and EPS growth of -87.07% year-over-year. On the balance sheet, it maintains a current ratio of 0.19x, a quick ratio of 0.15x, working capital of $-10.94M, a debt-to-equity ratio of 1.15x, a debt ratio of 0.54, an interest coverage ratio of -62.60x, free cash flow of $-9.37M (TTM), and net debt of $-643.00K. Figures sourced from SEC EDGAR.

Market Cap

$2.35M

P/E TTM

-0.19x

EPS TTM

$-4.43

P/B TTM

0.14x

ROE TTM

-103.56%

ROA TTM

-39.29%

Debt To Equity

1.15x

Free Cash Flow TTM

$-9.37M

Net Revenue TTM Growth 1Y

219.17%

Data as of 2026-06-30 · Source: SEC EDGAR